OVARIAN Non-commercial trials | ||
---|---|---|
Trial | Study description | Status |
ADRAPAC/ CEEGOG OX-03 documents available here |
Symptomatic Ascites Drainage with a Patient-controlled Vascular Catheter The target size of the group: 170 subjects |
Ongoing |
MITO33/ ENGOT-ov51 |
A Randomized phase III trial on Niraparib-TSR 042 vs physician’s choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment The target size of the group: 427 subjects |
Ongoing |
SOLERO/ ENGOT-OV64/NSGO-CTU |
An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer The target size of the group: 105 subjects |
Under preparation |
AGO-OVAR 28/ENGOT-ov57 | Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) The target size of the group: 970 subjects |
Under preparation |
HE4-FU-OVCA/ CEEGOG OX-01 documents available here |
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer A prospective multicentre observational study The target size of the group: 150 subjects |
Enrollment closed |
ATALANTE/ ENGOT-ov29/GINECO |
A randomized, double blinded, phase III study of Atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and Bevacizumab The target size of the group: 600 subjects |
Enrollment closed |
EXPRESSION VI/ ENGOT-ov40/NOGGO S13 |
Caroline meets HANNA – Holistic Analysis of longterm survivors with ovarian cancer The target size of the group: 100-200 subjects per participating country |
Closed |
CERVICAL Non-commercial trials | ||
---|---|---|
Trial | Study description | Status |
SENTICOL III/ ENGOT-cx4/GINECO |
International validation study of sentinel node biopsy in early cervical cancer The target size of the group: 950 subjects |
Ongoing |
RACE/ CEEGOG CX-06 documents available here |
Rare cervical tumour study The target size of the group: 300+ subjects |
Ongoing |
CERVANTES/ CEEGOG CX-05/ ENGOT-cx16 |
An international randomised trial of radical surgery followed by adjuvant (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer patients The target size of the group: 514 subjects |
Ongoing |
SENTIX/ CEEGOG CX-01/ ENGOT-cx2 documents available here |
Sentinel node in cervix cancer A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer The target size of the SLN Study group: 600 subjects The target size of the Control group: 100 subjects Estimated enrollment period: 2016 – 2020 |
Closed |
FERTISS/ CEEGOG CX-03/ ENGOT-cx14 documents available here |
FERTIlity Sparing Surgery in cervical cancer patients outside controlled trials | Closed |
RSS-EAC-PAT/ CEEGOG CX-04 documents available here |
The Risk Stratification System for endocervical adenocarcinoma based on tumor pattern and its clinical outcomes | Closed |
ABRAX/ CEEGOG CX2/ ENGOT-cx3 documents available here |
Oncological outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of LN positivity | Closed |
CoNteSSa/NeoCon-F | FIGO 2018 stage IB2(≥2cm ≤4cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa)/ Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F) The target size of the group: 90 subjects |
Preparation terminated |
ENDOMETRIAL Non-commercial trials | ||
---|---|---|
Trial | Study description | Status |
TESLA1/ CEEGOG EX-02 documents available here |
Tracers for Endometrial cancer Sentinel node LAbelling A Prospective observational study on sentinel node biopsy using two concurrent labelling techniques (radioactive tracer with/without blue dye vs. indocyanin green-ICG) in early-stage endometrial cancer patients The target size of the group: 83 subjects |
Ongoing |
REGYS/CEEGOG EX-03 documents available here |
Rare gynecological sarcoma study The target size of the group: 782 subjects |
Ongoing |
PORTEC-4a | Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer The target size of the group: 450 subjects |
Enrollment closed |
ENGOT-EN2-DGCG/ EORTC 55102 |
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer The target size of the group: 240 subjects |
Enrollment closed |
SALVAGE/ CEEGOG EX01 documents available here |
A retrospective trial on patients who have undergone salvage surgery for a recurrent uterine or cervical cancer Salvage database – data from 620 patients collected |
Closed |
OVARIAN Commercial trials | ||
---|---|---|
Trial | Study description | Status |
EPIK-O/ ENGOT-ov61/GEICO |
A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer The target size of the group: 358 subjects |
Ongoing |
BOUQUET/ ENGOT-GYN2/GINECO |
A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors The target size of the group: 80-200 subjects |
Ongoing |
AVB500-OC-004/ ENGOT-ov66/GEICO |
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer The target size of the group: 300 to 500 subjects |
Ongoing |
ARTISTRY-7/ ENGOT-ov68/NOGGO |
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer The target size of the group: 376 subjects |
Under preparation |
MER-XMT-1536-1/ UPLIFT/ ENGOT-ov67/AGO-A |
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b The target size of the group: 180 to 240 subjects |
Enrollment closed |
MIRASOL/ ENGOT-ov55/BGOG |
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression The target size of the group: 430 subjects |
Enrollment closed |
MK-7339-001-00/ ENGOT-ov43/BGOG |
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) The target size of the group: 1367 subjects |
Enrollment closed |
INNOVATE-3/ ENGOT-ov50/BGOG |
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC) The target size of the group: 540 subjects |
Enrollment closed |
FIRST/ ENGOT-ov44/GINECO |
A Patient‑centric, Randomized, Phase 3 comparison of Platinum‑based Therapy with or without bevacizumab to the same plus TSR‑042 as first‑line treatment of stage iii or iv non-mucinous ovarian cancer followed by maintenaNce therapy The target size of the group: 720 - 960 subjects |
Enrollment closed |
ATHENA/ ENGOT-ov45/NCRI |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy The target size of the group: 1000 subjects |
Enrollment closed |
IMAGYN050/ YO39523/GOG-3015/ ENGOT-ov39 |
A phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer The target size of the group: 1300 subjects |
Enrollment closed |
PRIMA/ ENGOT-ov26/GEICO/1509 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Studyof Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy The target size of the group: 620 subjects |
Enrollment closed |
SOTIO/ SOV01 |
SOV01 A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma The target size of the group: additional 30 subjects |
Closed |
SOTIO/ SOV06 |
SOV06 An open-label, single-group, multicenter phase II clinical trial evaluating the effect of maintenance DCVAC/OvCa after standard of care therapy in women with first relapse of platinum-sensitive epithelial ovarian carcinoma The target size of the group: 30 subjects |
Closed |
JAVELIN OVARIAN 200 | A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer Approximately 550 patients will be randomized |
Closed |
SOTIO/ SOV02 |
SOV02 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with relapsed platinum sensitive epithelial ovarian carcinoma | Closed |
SOTIO/ SOV03 |
SOV03 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy in women with relapsed platinum resistant epithelial ovarian carcinoma | Closed |
MILO/ ENGOT-ov11/BGOG |
MEK Inhibitor in Low-grade Serous Ovarian Cancer A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum |
Closed |
NOVA/ ENGOT-ov16/NSGO |
Niraparib in OVArian cancer A randomized, double-blind phase 3 trial of maintenance with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer |
Closed |
SOV09/VITALIA/ ENGOT-ov53/CEEGOG |
A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma The target size of the group: 678 subjects |
Preparation terminated |
CERVICAL Commercial trials | ||
---|---|---|
Trial | Study description | Status |
GCT1015-05/ ENGOT-cx8/BGOG |
A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer The target size of the group: 140 subjects |
Ongoing |
KEYNOTE-A18/ ENGOT-cx11/MITO |
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer The target size of the group: 980 subjects |
Ongoing |
GCT1015-07/ ENGOT-cx12/BGOG |
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer The target size of the group: 486 subjects |
Ongoing |
GCT1015-04/ ENGOT-cx6/BGOG |
A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®‑TF‑ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer The target size of the group: 100 subjects |
Enrollment closed |
FERMATA/ ENGOTcx13/AGO |
An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer The target size of the group: 316 subjects |
Preparation terminated |
BRAVA/ ENGOT-cx17/GINECO |
A Phase 3 Trial of Balstilimab versus Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer after Platinum-Based Chemotherapy The target size of the group: 486 subjects |
Preparation terminated |
ENDOMETRIAL Commercial trials | ||
---|---|---|
Trial | Study description | Status |
KEYNOTE-C93/ GOG-3064/ ENGOT-en15/MITO |
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting The target size of the group: 350 |
Ongoing |
RUBY/ ENGOT EN-6/NSGO |
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY) The target size of the group (PART I): 470 subjects The target size of the group (PART II): 270 subjects |
Enrollment closed |
KEYNOTE-B21/ ENGOT-en11/BGOG | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent The target size of the group: 990 subjects |
Enrollment closed |
DUO-E/ ENGOT EN-10/BGOG |
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumabwith or without Olaparibin Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer The target size of the group: 699 subjects |
Enrollment closed |
SIENDO/ ENGOT-EN5/BGOG-EN5 |
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer. The target size of the group: 248 subjects |
Enrollment closed |